BridgeMD
New treatment option for Community-acquired Pneumonia, Influenza, COVID-19
Official title Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
ClinicalTrials.gov ID: NCT02735707
What this study is testing
What is Ceftriaxone?
Ceftriaxone is an investigational medicine, being studied as a potential treatment for community-acquired pneumonia, influenza, covid-19.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- REMAP-CAP PLATFORM
- Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with:
- symptoms or signs or both that are consistent with lower respiratory tract infection AND
- Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
- Up to 48 hours after ICU admission, receiving organ support with one or more of:
You likely can't join if
- Healthcare-associated pneumonia:
- Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days
- Resident of a nursing home or long term care facility
- Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending...
- Previous participation in this REMAP within the last 90 days REMAP-COVID PLATFORM INCLUSION CRITERIA 1\. Adult patients (≥ 18 years) admitted to...
- Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending...
See the full eligibility criteria
- REMAP-CAP PLATFORM
- Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with:
- symptoms or signs or both that are consistent with lower respiratory tract infection AND
- Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
- Up to 48 hours after ICU admission, receiving organ support with one or more of:
- Non-invasive or Invasive ventilatory support;
- Receiving infusion of vasopressor or inotropes or both PLATFORM
- Healthcare-associated pneumonia:
- Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days
- Resident of a nursing home or long term care facility
- Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
- Previous participation in this REMAP within the last 90 days REMAP-COVID PLATFORM INCLUSION CRITERIA 1\. Adult patients (≥ 18 years) admitted to hospital with acute illness due to suspected or proven pandemic infection...
- Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
- Patient is expected to be discharged from hospital today or tomorrow
- More than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection.
- Previous participation in this REMAP within the last 90 days DOMAIN-SPECIFIC ELIGIBLE CRITERIA: Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).
The study team makes the final eligibility decision.
Where it's taking place
- Jacksonville, Florida, United States
- Augusta, Georgia, United States
- Chicago, Illinois, United States
- New Orleans, Louisiana, United States
- Ann Arbor, Michigan, United States
- New York, New York, United States
- Winston-Salem, North Carolina, United States
- Columbus, Ohio, United States
- Portland, Oregon, United States
- Pittsburgh, Pennsylvania, United States
- Providence, Rhode Island, United States
- Canberra, Australian Capital Territory, Australia
- Bankstown, New South Wales, Australia
- Blacktown, New South Wales, Australia
- Campbelltown, New South Wales, Australia
- Caringbah, New South Wales, Australia
- Concord, New South Wales, Australia
- Dubbo, New South Wales, Australia
- Frenchs Forest, New South Wales, Australia
- Kingswood, New South Wales, Australia
+ 288 more site(s).
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Jacksonville, Florida, United States; Augusta, Georgia, United States; Chicago, Illinois, United States; New Orleans, Louisiana, United States; Ann Arbor, Michigan, United States; New York, New York, United States and 302 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.